Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

Etavopivat improved hemoglobin levels and reduced pain crises in a Phase 3 sickle cell disease trial, supporting potential ...

Shares of Agios Pharmaceuticals AGIO declined sharply by 23% on Monday after Novo Nordisk NVO announced positive top-line ...

Novo Nordisk NVO announced meeting both co-primary endpoints in a late-stage study of its investigational candidate, etavopivat, for adults and adolescents with sickle cell disease (SCD). The data ...

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / ...

Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

"We need effective anti-bias interventions to improve care for patients with sickle cell disease, and this deeper understanding is a step in the right direction," said the study author.

SCD is a fund I've provided coverage on quite regularly as it's a unique fund. The fund carries a portfolio of MLPs and tech as its largest weightings though it is somewhat diversified overall, too, ...